Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20463074 | 0.93 | EPHX2 (0.41) | ALDH1A1EPHX2TSHRLMNARECQL | |
| SCHEMBL25123095 | 0.89 | FAAH (0.45) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| SCHEMBL15855135 | 0.89 | FAAH (0.45) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| SCHEMBL15855136 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAKMT2AMAPT | |
| SCHEMBL25885112 | 0.85 | EPHX2 (0.43) | ALDH1A1EPHX2TSHRLMNARECQL | |
| SCHEMBL25830736 | 0.85 | KMT2A (0.52) | ALDH1A1EPHX2TSHRLMNARECQL | |
| SCHEMBL23696123 | 0.85 | KDM4E (0.48) | ALDH1A1EPHX2TSHRLMNARECQL | |
| SCHEMBL24508250 | 0.84 | KDM4E (0.47) | ALDH1A1EPHX2TSHRLMNARECQL | |
| SCHEMBL22906477 | 0.84 | FAAH (0.53) | EPHX2TSHRRECQLKMT2AMAPT | |
| SCHEMBL23559960 | 0.84 | KMT2A (0.50) | ALDH1A1EPHX2TSHRLMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ALDH1A1 2819/4885EPHX2 2761/4885TSHR 1081/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ALDH1A1 2819/4885EPHX2 2761/4885TSHR 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.